Acta Scientific Pharmaceutical Sciences

Short CommunicationVolume 2 Issue 8

Zostavax vs. Shingrix – Which Should Pharmacists Recommend

Ali Chaudhry*

Shoppers Drug Mart, Thunder Bay, Canada

*Corresponding Author: Ali Chaudhry, Shoppers Drug Mart, Thunder Bay, Canada.

Received: June 22, 2018; Published: July 03, 2018

Citation: Ali Chaudhry.“Zostavax vs. Shingrix – Which Should Pharmacists Recommend”. Acta Scientific Pharmaceutical Sciences 2.8 (2018).

   With the release of the new vaccine Shingrix for the prevention of shingles and postherpetic neuralgia, it begs the question as to whether this new vaccine is any better than the current vaccine, Zostavax. Pharmacists are in a unique position to help identify patients who are at risk of developing shingles, and by knowing which vaccine is better suited for a patient, can potentially help a patient from long term suffering.

Copyright: © 2018 Ali Chaudhry. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate32%
Acceptance to publication20-30 days

Indexed In




News and Events


  • Reviewer Certificate
    Certificate will be issues to the valued reviewer who worked on the Articles Peer Review process.
  • Publication Certificate
    Authors will be provided with the Publication Certificate after their successful publication
  • Last Date for submission
    Authors are requested to submit their manuscripts before September 30, 2025

Contact US